BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Immix Biopharma (IMMX)Immix Biopharma2026-06-25 13:46 ESTClinical readout

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201...

Open original release

Related news

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Proposed Public Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma 12 Month Review Progress Update

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative

View all latest news

Immix Biopharma

Immix Biopharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

IMMXImmix Biopharma2026-06-26 09:56 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-26 09:56 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-26 09:56 EST

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

IMMXImmix Biopharma2026-06-26 09:56 EST

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

IMMXImmix Biopharma2026-06-26 09:56 EST

Immix Biopharma Announces Proposed Public Offering of Common Stock

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States